SarcoFit: Effect of Protein Supplementation and a Structured Exercise Program on Muscle in Women After Bariatric Surgery.

Sponsor
Hospital Clinic of Barcelona (Other)
Overall Status
Recruiting
CT.gov ID
NCT04771377
Collaborator
Garmin International (Industry), Institut Nacional d'Educacio Fisica de Catalunya (Other)
75
1
3
15
5

Study Details

Study Description

Brief Summary

Obesity is considered a chronic disease that increases the risk of developing diseases that reduce life expectancy. The treatment of obesity is complex. However, treatments based exclusively on dietary changes have not shown long-term efficacy especially in people with severe obesity. In contrast, in this group of people bariatric surgery (BS) has shown good long-term results in weight loss and maintenance. These changes are accompanied by significant improvements in health, improved quality of life, and reduced mortality. However, the changes in the digestive system created by BS and the high level of dietary restriction, affect the nutritional status and require a proper supplementation of vitamins and minerals during the follow-up. Intense weight loss during the first few months, coupled with an insufficient amount of protein in the diet, can lead to a loss of muscle mass. Excessive muscle loss during the short-term period can lead to functional repercussions (decreased strength and physical function) and reduced calories that the body burns daily. Naturally, this is especially important in people suffering from sarcopenia before BS, and it occurs more frequently in postmenopausal women. Despite this is known, specific protein intake recommendations after BS have not yet been defined based on scientific evidence. In this context, the first part of our proposal will assess the effect of two levels of protein supplementation: standard (S-PS) versus high (H-PS) on changes in a) body composition, b) energy expenditure, c) metabolic flexibility d) the physical condition during weight loss that follows BS. In addition, in patients with H-PS, the added effect of a physical exercise program, carried out with a personal trainer (professional of sports medicine trainer) virtually, will be evaluated. Protein supplementation and the virtual exercise program will be done during the 4 months following BS, and the results will be studied at 4, 8, and 12 months. Once the results have been defined, it is essential to transfer the recommendations to the real world. In a second part, and to achieve knowledge transfer to clinical practice, the investigators will explore the key elements that influence patient experience (XPA).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Protein Supplementation
N/A

Detailed Description

Obesity is considered a chronic disease that increases the risk of developing diseases that reduce life expectancy. The treatment of obesity is complex. However, treatments based exclusively on dietary changes have not shown long-term efficacy especially in people with severe obesity. In contrast, in this group of people bariatric surgery (BS) has shown good long-term results in weight loss and maintenance. These changes are accompanied by significant improvements in health, improved quality of life, and reduced mortality. However, the changes in the digestive system created by BS and the high level of dietary restriction, affect the nutritional status and require a proper supplementation of vitamins and minerals during the follow-up. Intense weight loss during the first few months, coupled with an insufficient amount of protein in the diet, can lead to a loss of muscle mass. Excessive muscle loss during the short-term period can lead to functional repercussions (decreased strength and physical function) and reduced calories that the body burns daily. Naturally, this is especially important in people suffering from sarcopenia before BS, and it occurs more frequently in postmenopausal women. Despite this is known, specific protein intake recommendations after BS have not yet been defined based on scientific evidence. In this context, the first part of our proposal will assess the effect of two levels of protein supplementation: standard (SP-S) versus high (SP-A) on changes in a) body composition, b) energy expenditure, c) metabolic flexibility d) the physical condition during weight loss that follows BS. In addition, in patients with SP-Alta, the added effect of a physical exercise program, carried out with a personal trainer (professional of sports medicine trainer) virtually, will be evaluated. Protein supplementation and the virtual exercise program will be done during the 4 months following CO, and the results will be studied at 4, 8, and 12 months. Once the results have been defined, it is essential to transfer the recommendations to the real world. In a second part, and to achieve knowledge transfer to clinical practice, the investigators will explore the key elements that influence patient experience (XPA). The investigators will define indicators to assess it, especially those that are related to adherence to nutritional recommendations and to changes in lifestyle. The investigators are currently in the recruitment phase of the study. I have studied the necessary elements, ambitions and included the components that will help to define the dietary and lifestyle recommendations for our population. Aim to facilitate and define the performance of the professionals providing realistic, based on the XPA and in this way to improve the impact of the CO on health and quality of life. This is an ambitious and necessary study and includes all the component that will help define dietary and lifestyle recommendations for our population. It aims to facilitate and define the action of professionals provides realistic tools, based on XPA and thus improve the impact of BS on health and quality of life.

Description of the population to study sedentary women, candidates for BS at our institution.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
2:2:1.2:2:1.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Protein Supplementation and a Structured Physical Exercise Program on Changes in Body Composition, Metabolic Flexibility (Energy Consumption of Substrates), and Functionality in Women During Weight Loss Induced by Bariatric Surgery.
Actual Study Start Date :
Nov 10, 2020
Anticipated Primary Completion Date :
Dec 10, 2021
Anticipated Study Completion Date :
Feb 10, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: standard protein supplementation (SPS)

0.8g protein/ IBW/ day

Dietary Supplement: Protein Supplementation
protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
Other Names:
  • Physical training
  • standard protein supplementation
  • Experimental: High protein supplementation (HPS)

    1.2g protein/ IBW/ day

    Dietary Supplement: Protein Supplementation
    protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
    Other Names:
  • Physical training
  • standard protein supplementation
  • Experimental: HPS + PA

    1.2g protein/ IBW/ day + PA 3 times a week/ 12 weeks

    Dietary Supplement: Protein Supplementation
    protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
    Other Names:
  • Physical training
  • standard protein supplementation
  • Outcome Measures

    Primary Outcome Measures

    1. effect of PS and PA on Changes in fat mass and Fat free mass (kg) [4 months after BS]

      change from baseline in DEXA values

    2. effect of PS and PA on Changes in fat mass and Fat free mass (kg) [8 months after BS]

      change from baseline in DEXA values

    3. effect of PS and PA on Changes in fat mass and Fat free mass (kg) [12 months after BS]

      change from baseline in DEXA values

    4. effect of PS and PA on resting energy expenditure (REE) (Kcal/ day) [4 months after BS]

      change from baseline in estimated REE from indirect calorimety

    5. effect of PS and PA on resting energy expenditure (REE) (Kcal/ day) [8 months after BS]

      change from baseline in estimated REE from indirect calorimety

    6. effect of PS and PA on resting energy expenditure (REE) (Kcal/ day) [12 months after BS]

      change from baseline in estimated REE from indirect calorimety

    7. Strength [4 months after BS]

      changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.

    8. Strength [8 months after BS]

      changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.

    9. Strength [12 months after BS]

      changes from baseline on prediction of ne repetition máximum (1-RM) and hang grip.

    10. Functionality [4 months after BS]

      changes from baseline on sit and stand

    11. Functionality [8 months after BS]

      changes from baseline on sit and stand

    12. Functionality [12 months after BS]

      changes from baseline on sit and stand

    13. Metabolic flexibility - oxidation of substrates: VO2 peak [4 months after BS]

      change in VO2 peak measured by Ergocard during half-effort test

    14. Metabolic flexibility - oxidation of substrates: VO2 peak [8 months after BS]

      change in VO2 peak measured by Ergocard

    15. Metabolic flexibility - oxidation of substrates: VO2 peak [12 months after BS]

      change in VO2 peak measured by Ergocard during half-effort test

    16. Respiratory quotient [4 months after BS]

      change in RQ determined by Ergocard during half-effort test

    17. Respiratory quotient [8 months after BS]

      change in RQ determined by Ergocard during half-effort test

    18. Respiratory quotient [12 months after BS]

      change in RQ determined by Ergocard during half-effort test

    19. Fat oxidation (FatMax) during during half-effort test [4 months after BS]

      Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)

    20. Fat oxidation (FatMax) during during half-effort test [8 months after BS]

      Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)

    21. Fat oxidation (FatMax) during during half-effort test [12 months after BS]

      Time to spend to reach the cross over pony for RQ=1 determined by Ergocard during half-effort test (min)

    22. Adherence to PS (BCAA biomarker) [4 months after BS]

      serum change in BCAA (mcg)

    23. Adherence to PS (BCAA biomarker) [8 months after BS]

      serum change in BCAA (mcg)

    24. Adherence to PS (BCAA biomarker) [12 months after BS]

      serum change in BCAA (mcg)

    25. Adherence to PS (urinary nitrogen 24hs.) [4 months after BS]

      Nitrogen (mg) values quantified in 24hs urine

    26. Adherence to PS (urinary nitrogen 24hs.) [8 months after BS]

      Nitrogen (mg) values quantified in 24hs urine

    27. Adherence to PS (urinary nitrogen 24hs.) [12 months after BS]

      Nitrogen (mg) values quantified in 24hs urine

    28. Understand patients' priorities and the "painful points" of the care process. Explore the magnitude of these "painful points." This should make it possible to prioritize the areas to be evaluated. Test assessment tools [12 months after BS]

      identify by focus group patient reported outcomes by cualitative study

    Secondary Outcome Measures

    1. Changes in BMI [4 months after BS]

      weight and height will be combined to report BMI in kg/m^2

    2. Changes in BMI [8 months after BS]

      weight and height will be combined to report BMI in kg/m^2

    3. Changes in BMI [12 months after BS]

      weight and height will be combined to report BMI in kg/m^2

    4. Insulin sensitivity (HOMA-IR) [4 months after BS]

      fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in

    5. Insulin sensitivity (HOMA-IR) [8 months after BS]

      fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in

    6. Insulin sensitivity (HOMA-IR) [12 months after BS]

      fasting glucose (mg) and insulin (miliunits/ liter) will be combined to report Insulin sensitivity in

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    45 Years to 75 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    women ≥45 years of age who meet CB criteria: Body mass index (BMI) ≥40.0 kg / m2 or between 35.0 and 39.9 kg / m2 with comorbidities (metabolic diseases, cardiorespiratory diseases), sedentary lack of regular physical activity: <30 minutes / day and <3 days / week).

    Exclusion Criteria:
    • presence of severe joint disease, severe liver disease, history of cardiovascular event or known heart disease, renal failure (defined as a FG <30 ml / min), type 1 or type 2 diabetes with HbA1c> 10%, being treated with drugs that may affect body composition (such as corticosteroids), exercise muscle strength-endurance regularly (more than 2 times / week), have previously undergone obesity surgery.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Clinic Barcelona Barcelona Spain 08036

    Sponsors and Collaborators

    • Hospital Clinic of Barcelona
    • Garmin International
    • Institut Nacional d'Educacio Fisica de Catalunya

    Investigators

    • Principal Investigator: Violeta L Moizé, PhD, Hospital Clinic of Barcelona

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hospital Clinic of Barcelona
    ClinicalTrials.gov Identifier:
    NCT04771377
    Other Study ID Numbers:
    • HCB/2020/0028
    First Posted:
    Feb 25, 2021
    Last Update Posted:
    Feb 25, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hospital Clinic of Barcelona
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 25, 2021